MCT® can be used in numerous therapeutic areas such as: Malaria, Influenza, Immunotherapy & Cancer

MCT® is available for out licensing and can also be requested for independent evaluation (via Material Transfer Agreements)

The National Institute of Health (NIH) have also listed the MCT® profile on their vaccine adjuvant compendium database (VAC) – Click here

The Vaccine Adjuvant Compendium (VAC) aims to foster collaborations between NIAID-supported adjuvant researchers and the broader scientific community to help vaccine developers identify suitable adjuvants

For further information on leveraging MCT® to innovate in healthcare, please contact enquiries@bencard-as.com